New 2022 ADA/EASD guidelines: GLPP-1 RA/Insulin combination is recommended
ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.
![](/.imaging/webp/sanofi-templates/article-hero-w768/dam/campus-sanofi-qa/Article-Images/science-hero-(2)-(1).jpg7/jcr:content/science%20hero%20(2)%20(1).jpg)